A 4 Month Extension to a 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.

Trial Profile

A 4 Month Extension to a 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2011

At a glance

  • Drugs Aliskiren; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Feb 2011 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Additional locations added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top